eptor Tyrosine Kinase Signaling Favors a Protumorigenic te in Breast Cancer Cells by Inhibiting the Adaptive
暂无分享,去创建一个
T. Pawson | L. Coussens | M. Hallett | W. Muller | D. Brennan | W. Gallagher | W. R. Hardy | C. Piccirillo | E. Rexhepaj | K. Jirstrom | Eva Bjur | D. Zuo | Lam | Babette Schade | S. Cory | Ursini-Siegel | DeNardo | Park
[1] P. Watson,et al. Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model , 2010, Breast Cancer Research and Treatment.
[2] Metin N. Gurcan,et al. Pten in Stromal Fibroblasts Suppresses Mammary Epithelial Tumors , 2009, Nature.
[3] R. Cardiff,et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.
[4] M. Ellis,et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.
[5] L. Coussens,et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.
[6] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] W. Paul,et al. CD4 T cells: fates, functions, and faults. , 2008, Blood.
[8] J. Van Damme,et al. The role of CXC chemokines and their receptors in cancer. , 2008, Cancer letters.
[9] J. Ursini-Siegel,et al. The ShcA adaptor protein is a critical regulator of breast cancer progression , 2008, Cell cycle.
[10] L. Akslen,et al. Expression of EGFR and c‐kit is associated with the basal‐like phenotype in breast carcinomas of African women , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[11] F. Pépin,et al. Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.
[12] L. Coussens,et al. Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.
[13] T. Pawson,et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.
[14] John N Weinstein,et al. A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.
[15] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[16] R. Cardiff,et al. Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. , 2007, Cancer research.
[17] L. Coussens,et al. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.
[18] J. Fawcett,et al. Combinatorial ShcA Docking Interactions Support Diversity in Tissue Morphogenesis , 2007, Science.
[19] Xinrong Ma,et al. Immune-mediated Modulation of Breast Cancer Growth and Metastasis by the Chemokine Mig (CXCL9) in a Murine Model , 2007, Journal of immunotherapy.
[20] T. Pawson,et al. Analysis of a Shc Family Adaptor Protein, ShcD/Shc4, That Associates with Muscle-Specific Kinase , 2007, Molecular and Cellular Biology.
[21] Lisa M. Coussens,et al. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .
[22] T. Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.
[23] K. Polyak. Pregnancy and breast cancer: the other side of the coin. , 2006, Cancer cell.
[24] S. Wiseman,et al. Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival , 2005, Cancer.
[25] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[26] W. Muller,et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.
[27] T. Pawson,et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[28] Jeffrey W Pollard,et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.
[29] R. Bagdasaryan,et al. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. , 2003, Cancer research.
[30] S. Szabo,et al. T-bet regulates IgG class switching and pathogenic autoantibody production , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Moran,et al. Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.
[32] L. Glimcher,et al. Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.
[33] W. Birchmeier,et al. Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.
[34] P. Blume-Jensen,et al. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction , 1999, Oncogene.
[35] M. Debenedette,et al. T cell co-stimulatory molecules other than CD28. , 1999, Current opinion in immunology.
[36] J. Koland,et al. Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.
[37] John N. Hutchinson,et al. Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.
[38] M. Moran,et al. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.
[39] T. Pawson,et al. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[40] B. Margolis,et al. The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor , 1995, Molecular and cellular biology.
[41] R. Cardiff,et al. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.
[42] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.